If you're seeing this message, that means
JavaScript has been disabled on your browser
, please
enable JS
to make this app work.
No tags found
Companies
No companies found
Advanced Search
Newsfeed
Alerts
Saved Lists
Sign Up for Free
Login
Get Updates
1,602
Followers on Owler
Alnylam
is a Massachusetts-based biopharmaceutical company that develops RNA interference therapeutics for genetically defined diseases...
Read more
Overview
Competitors
Acquisitions
Funding
News & Insights
Alnylam
is a Massachusetts-based biopharmaceutical company that develops RNA interference therapeutics for genetically defined diseases...
Read more
CEO
John Maraganore
CEO Approval Rating
88/100
Weigh In
2002
Cambridge
Massachusetts
Greater Boston
Public
NASDAQ
ALNY
Pharmaceuticals & Biotechnology
Biotechnology
2834
NAICS listing
https://www.alnylam.com/
Annual Revenue
$4.3B
Employees
2,000
Funding
$5.3B
Acquisitions
1
News
Key Events
Latest News
Partnership
Sep 20, 2025
Pharmabiz
Alnylam Pharma joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
Funding
Sep 10, 2025
Nasdaq
Alnylam received $575M in Post-IPO Debt Funding
Follow and Get Alerts
Alnylam Competitors
1
Follow
2
Follow
3
Follow
4
Follow
5
Follow
6
Follow
7
Follow
8
Follow
9
Follow
10
Follow
Unlock 12 + competitors
Trending Companies
